Why This Biotech Crushed the Market

In the following video, health care editor/analyst David Williamson discusses the FDA advisory committee vote that sent shares of Arena Pharmaceuticals soaring over 70% in a single day. Obesity drug lorcaserin received an 18-4 recommendation supporting approval. What does this vote mean for Arena's competitors, and is the company poised for monster returns? For a closer look, watch the video and Fool On.

Author

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid